[Phe4]somatostatin: a potent, selective inhibitor of growth hormone release.
[Phe4]Somatostatin was twice as active as somatostatin (SS) in suppressing rat growth hormone release in vitro but had only weak activity toward inhibition of insulin and glucagon release in vivo. The ability of this analogue to inhibit growth hormone release more actively than SS was confirmed in vivo by two separately designed bioassays. Further structure/activity studies of position 4 were carried out with [Glu4]SS, [Thr4]SS, and des-Lys4-SS, all of which had negligible inhibiting activity in the pituitary and pancreas. In this context the strikingly selective activity of [Phe4]SS suggests a fundamental difference in the SS receptors of pituitary and pancreas and the normal side-chain basicity of position 4 appears to be more important for action in pancreas than in pituitary. [Phe4]SS has properties that may be useful in the development of agents for the treatment of acromegaly or other disorders associated with increased growth hormone levels.
D000595:Amino Acid Sequence; D000818:Animals; D002478:Cells, Cultured; D005934:Glucagon / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism*; D006728:Hormones / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D010649:Phenylalanine; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D051381:Rats; D013004:Somatostatin / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D006728:Hormones; D007328:Insulin; D010649:Phenylalanine; D013004:Somatostatin; D013006:Growth Hormone; D005934:Glucagon